EPISODE · Apr 1, 2026 · 9 MIN
CLL at ASH 2025: CLL17
from Medical News Podcast · host PeerDirect Publishing
Drs. O’Brien and Wierda discuss how fixed-duration venetoclax-based therapy can match continuous BTK inhibitor treatment in CLL while offering deep remissions and time off therapy. They also explore promising real-world CAR T-cell (liso-cel) results and stress the growing importance of vaccination and cancer screening as CLL patients live longer.
Embed this episode
NOW PLAYING
CLL at ASH 2025: CLL17
0:00
9:07
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Medical News Podcast?
This episode is 9 minutes long.
When was this Medical News Podcast episode published?
This episode was published on April 1, 2026.
Can I download this Medical News Podcast episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!